{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"submitter":["Otto C"],"funding":["Bundesministerium für Bildung und Forschung","Berlin Institute of Health","Berlin University Alliance","Stiftung Charité"],"pubmed_abstract":["<h4>Objective</h4>To analyze anti-SARS-CoV-2-S1-IgG levels, avidity, Omicron BA.2 variant neutralizing capacity, and SARS-CoV-2-specific T cells in anti-CD20-treated patients with multiple sclerosis (aCD20pwMS) after two, three, or four COVID-19 vaccinations.<h4>Results</h4>Frequencies of aCD20pwMS with detectable SARS-CoV-2-S1-IgG increased moderately between two (31/61 (51%)), three (31/57 (54%)), and four (17/26 (65%)) vaccinations. However, among patients with detectable SARS-CoV-2-S1-IgG, frequencies of high avidity (6/31 (19%) vs 11/17 (65%)) and Omicron neutralizing antibodies (0/10 (0%) vs 6/10 (60%)) increased strongly between two and four vaccinations. SARS-CoV-2-specific T cells were detectable in >92% after two or more vaccinations.<h4>Conclusion</h4>Additional vaccinations qua"],"journal":["Multiple sclerosis (Houndmills, Basingstoke, England)"],"pagination":["13524585231161253"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10051002"],"repository":["biostudies-literature"],"pubmed_title":["Humoral immune responses remain quantitatively impaired but improve qualitatively in anti-CD20-treated patients with multiple sclerosis after three or four COVID-19 vaccinations."],"pmcid":["PMC10051002"],"funding_grant_id":["BIH Clinical Fellow Program","BIH-Charité Clinician Scientist Program","01KI2021","01KX2021"],"pubmed_authors":["Otto C","Niederschweiberer M","Walper F","Jeworowski LM","Pache F","Schindler P","Ruprecht K","Schmidt ML","Schwarz T","Drosten C","Corman VM","Krumbholz A","Rose R"],"additional_accession":[]},"is_claimable":false,"name":"Humoral immune responses remain quantitatively impaired but improve qualitatively in anti-CD20-treated patients with multiple sclerosis after three or four COVID-19 vaccinations.","description":"<h4>Objective</h4>To analyze anti-SARS-CoV-2-S1-IgG levels, avidity, Omicron BA.2 variant neutralizing capacity, and SARS-CoV-2-specific T cells in anti-CD20-treated patients with multiple sclerosis (aCD20pwMS) after two, three, or four COVID-19 vaccinations.<h4>Results</h4>Frequencies of aCD20pwMS with detectable SARS-CoV-2-S1-IgG increased moderately between two (31/61 (51%)), three (31/57 (54%)), and four (17/26 (65%)) vaccinations. However, among patients with detectable SARS-CoV-2-S1-IgG, frequencies of high avidity (6/31 (19%) vs 11/17 (65%)) and Omicron neutralizing antibodies (0/10 (0%) vs 6/10 (60%)) increased strongly between two and four vaccinations. SARS-CoV-2-specific T cells were detectable in >92% after two or more vaccinations.<h4>Conclusion</h4>Additional vaccinations qua","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Mar","modification":"2025-05-29T14:38:02.359Z","creation":"2025-02-19T00:49:41.191Z"},"accession":"S-EPMC10051002","cross_references":{"pubmed":["36974938"],"doi":["10.1177/13524585231161253"]}}